InvestorsHub Logo
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

Re: falcon74 post# 346043

Sunday, 02/14/2021 3:38:48 PM

Sunday, February 14, 2021 3:38:48 PM

Post# of 403568
Awesome post and factually based! Tick tock...Thanks you

Go Leo & IPIX!

The truth is that a pre-"Peer Reviewed" article is reviewed by a number of experts in the field for both accuracy of reporting of the data and conclusions being drawn.

TWEEKING OF THE ARTICLE FROM THESE INDEPENDENT REVIEWERS...REGARDING ARTICULATING THE DATA and THE CONCLUSIONS REACHED IS AND WAS EXPECTED...LIKELY 100% OF THE PEER REVIEWED ARTICLES ARE MODIFIED.

Furthermore...the independent review reached the same conclusion of the independent research...BRILACIDIN "Exhibits POTENT IN VITRO ANTIVIRAL ACTIVITY AGAINST SARS-CoV-2"

Statements that Pre-Print was never going to be published, or that if it were published, it would be in the equivalent of "MAD Magazine", AGAIN IS WRONG!! We can agree to disagree but there is no doubt….I repeat … there is not doubt there is a NAKE SHORT position in IPIX. Eventually, the world will find out that this statement will be proven correct.

FACT…..Brilacidin has exhibited 97% viral load reductions in INDEPENDENT U.S. Biocontainment Lab Tests...with significant antiviral confirmation.

Individuals can disagree with the facts and state misrepresentations regarding the trials, but I believe the truth will come out when Leo releases his next PR regarding the trials (starting last week as PR'd) and other positive developments.

Lastly, when LEO releases the Clinical Trials sites, status reports and "other" positive developements...IMO, there will be a significant upturn in the share price as no forces will be able to hold the share price down!

Within a very short time, we will know whether longs like myself are correct.

Just "know what you own!"


Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation

FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals - Brilacidin for Treating
COVID-19

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News